Brief: Urogen Announces New Data From Olympus Trial That Shows Median Durability Of Response Of 28.9 Months For Jelmyto®

UroGen Pharma

02/12/2022 24:07

Dec 1 (Reuters) - Urogen Pharma Ltd  UR8.F :
    * UROGEN ANNOUNCES NEW DATA FROM OLYMPUS TRIAL THAT SHOWS
MEDIAN
DURABILITY OF RESPONSE OF 28.9 MONTHS FOR JELMYTO®
    * UROGEN PHARMA-13 PATIENTS REMAINED IN CR, TWO PATIENTS HAD
RECURRENCE OF LOW-GRADE UPPER TRACT UROTHELIAL CARCINOMA ON SAME
SIDE AS TREATED IN OLYMPUS
    * AT TIME OF DATA CUT OFF (FEB 25, 2022) NO PATIENT HAD
PROGRESSED
TO HIGH-GRADE DISEASE

Source text for Eikon:  ID:nBwbHJTVca 
Further company coverage:  UR8.F 
 ((Reuters.Briefs@thomsonreuters.com;))